Scarica l'app Stockscreener
28.18
0.32%
-0.09
Dopo l'orario di chiusura:
28.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.27
Aprire:
$28.44
Volume 24 ore:
1.48M
Relative Volume:
0.72
Capitalizzazione di mercato:
$2.60B
Reddito:
$333.87M
Utile/perdita netta:
$-169.00M
Rapporto P/E:
-13.81
EPS:
-2.04
Flusso di cassa netto:
$-157.30M
1 W Prestazione:
-3.95%
1M Prestazione:
-11.05%
6M Prestazione:
+33.24%
1 anno Prestazione:
+43.05%
Intervallo 1D:
$27.85
$28.59
Intervallo di 1 settimana:
$27.85
$30.15
Portata 52W:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
28.18 | 2.61B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Vanguard Group Inc. Has $158.06 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Legato Capital Management LLC Acquires Shares of 71,030 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance
Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - Sahm
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to Buy - MarketBeat
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins - MSN
Travere Therapeutics Earnings Call Shows Growth Amid Risks - TipRanks
TVTX (NASDAQ): Affiliate files Form 144 to sell 60,000 shares - Stock Titan
How liquid is Travere Therapeutics Inc. stockJuly 2025 Volume & Daily Chart Pattern Signals - mfd.ru
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights - GuruFocus
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics Q4 Earnings Call Highlights - MarketBeat
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
TVTX: FILSPARI drove record revenue and patient growth in 2025, with strong outlook for 2026 - TradingView
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
TVTX: 2025 revenue surged to $490.7M on FILSPARI growth; net loss narrowed and pipeline advanced - TradingView
Travere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss - Investing.com Canada
Travere: Fourth Quarter Financial Results Overview - Bitget
Travere: Q4 Earnings Snapshot - KVUE
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q4 Adjusted EPS $0.37 per Share, vs. FactSet Est of $0.38 - marketscreener.com
FILSPARI surge drives Travere Therapeutics (TVTX) to 2025 non-GAAP profit - Stock Titan
Travere Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
Travere Therapeutics faces earnings test amid FSGS approval delay By Investing.com - Investing.com UK
Travere Therapeutics faces earnings test amid FSGS approval delay - Investing.com Australia
Stocks with rising relative price strength: Travere Therapeutics - MSN
Earnings Outlook For Travere Therapeutics - Benzinga
Aberdeen Group plc Acquires 70,791 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market - Finviz
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unpacking A 52.25% Potential Upside - DirectorsTalk Interviews
How New Filspari Reviews And Price Targets Are Rewriting The Story For Travere Therapeutics (TVTX) - Yahoo Finance
Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility? - Yahoo Finance
Precision Trading with Travere Therapeutics Inc. (TVTX) Risk Zones - Stock Traders Daily
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):